Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826043 | 0.77 | — | — | |
| SCHEMBL19736599 | 0.76 | ATM (0.39) | ATMFFAR2RAB9ANPC1POLB | |
| Hydrochloric Acid SCHEMBL14743836 | 0.75 | — | — | |
| SCHEMBL5803747 | 0.72 | — | — | |
| SCHEMBL10802281 | 0.72 | — | — | |
| SCHEMBL19930552 | 0.72 | NUDT1 (0.47) | ATMHRH4RAB9ANPC1POLB | |
| SCHEMBL21790451 | 0.72 | ATM (0.45) | ATMHCAR3FFAR2RAB9ANPC1 | |
| SCHEMBL146802 | 0.69 | — | — | |
| SCHEMBL18809573 | 0.69 | — | — | |
| SCHEMBL145144 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362478-A1 | CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-12-15 | — | — | US | disclosed |
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-7465728-B2 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | ESR1 2828/4885ATM 4415/4885HCAR3 4275/4885 |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | OXER1, ALOX12, CYP1A1 | ESR1 604/4885ATM 4856/4885HCAR3 112/4885 |
| US-20050131000-A1 | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity | CCNI, CDK2, CDK1 | ESR1 3197/4885ATM 1035/4885HCAR3 3398/4885 |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | ESR1 1323/4885ATM 3068/4885HCAR3 1783/4885 |
| US-20160362478-A1 | CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES | CD4, CD14, CD81 | ESR1 1476/4885ATM 2237/4885HCAR3 3865/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | ESR1 343/4885ATM 4097/4885HCAR3 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.